Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-09-29

AUTHORS

A Okines, O del Puerto, D Cunningham, I Chau, E Van Cutsem, L Saltz, J Cassidy

ABSTRACT

Background:Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.Methods:First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.Results:In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42–100) after the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and 1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P=0.002), possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701 patients treated with placebo (4.9%) underwent R0 metastasectomy (P=0.24).Conclusions:The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bevacizumab vs placebo. More... »

PAGES

1033-1038

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259

DOI

http://dx.doi.org/10.1038/sj.bjc.6605259

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048476579

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19789532


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postoperative Complications", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okines", 
        "givenName": "A", 
        "id": "sg:person.011120523514.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120523514.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "F Hoffman La Roche Ltd, Welwyn Garden City, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "F Hoffman La Roche Ltd, Welwyn Garden City, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puerto", 
        "givenName": "O del", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "D", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chau", 
        "givenName": "I", 
        "id": "sg:person.01035560774.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Cutsem", 
        "givenName": "E", 
        "id": "sg:person.01214007230.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214007230.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center, New York City, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, New York City, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saltz", 
        "givenName": "L", 
        "id": "sg:person.011701556564.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011701556564.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research UK, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.11485.39", 
          "name": [
            "Cancer Research UK, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cassidy", 
        "givenName": "J", 
        "id": "sg:person.015665060162.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015665060162.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-007-0588-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029987674", 
          "https://doi.org/10.1007/s00280-007-0588-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040702997", 
          "https://doi.org/10.1038/sj.bjc.6603670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10434-001-0347-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015538540", 
          "https://doi.org/10.1007/s10434-001-0347-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-09-29", 
    "datePublishedReg": "2009-09-29", 
    "description": "Background:Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.Methods:First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.Results:In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42\u2013100) after the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and 1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P=0.002), possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701 patients treated with placebo (4.9%) underwent R0 metastasectomy (P=0.24).Conclusions:The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bevacizumab vs placebo.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605259", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "101"
      }
    ], 
    "keywords": [
      "curative-intent surgery", 
      "serious post-operative complications", 
      "first-line chemotherapy", 
      "post-operative complications", 
      "resection rate", 
      "first beat", 
      "oxaliplatin-based combination chemotherapy", 
      "safety of bevacizumab", 
      "grade 3/4 bleeding", 
      "metastatic colorectal cancer", 
      "oxaliplatin-based chemotherapy", 
      "surgery-related deaths", 
      "NO16966 trial", 
      "last dose", 
      "R0 resection", 
      "overall survival", 
      "complete resection", 
      "combination chemotherapy", 
      "patient selection", 
      "different regimens", 
      "colorectal cancer", 
      "historical controls", 
      "retrospective analysis", 
      "bevacizumab", 
      "patients", 
      "chemotherapy", 
      "NO16966", 
      "placebo", 
      "surgery", 
      "wound-healing events", 
      "resection", 
      "complications", 
      "significant differences", 
      "beats", 
      "metastasectomy", 
      "bleeding", 
      "regimens", 
      "exploratory comparison", 
      "metastasis", 
      "cancer", 
      "dose", 
      "trials", 
      "rate", 
      "efficacy", 
      "death", 
      "cure", 
      "survival", 
      "days", 
      "safety", 
      "differences", 
      "control", 
      "events", 
      "data", 
      "comparison", 
      "analysis", 
      "selection"
    ], 
    "name": "Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial", 
    "pagination": "1033-1038", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048476579"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605259"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19789532"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605259", 
      "https://app.dimensions.ai/details/publication/pub.1048476579"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_492.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605259"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      97 URIs      86 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605259 schema:about N0690699cd469474d8bfdb4cafffaeb40
2 N0a0f6f9ef7af4b5594c36f29c85dbb97
3 N0f458a6ecf704884bda34230cfc5f1c9
4 N162d56e9d0b546dd99e21837e81c2088
5 N31b8d8bb1ea540ef965a270f60b53d57
6 N66793de34d3744ce9cb1a309df6d695b
7 N81c4d5ee2a2b4cccb5261358409a8a67
8 N9378d53606ae4bd4b669e17354d441dc
9 N93f776b132f341b880fdf64600080324
10 N9436d8006012454a9a7e7628dd98c1a2
11 N9c4d01ea3eaf4b3eb8cccedad0cbf429
12 Na8de514677c847ab9f49ea6bbadb9556
13 Ndffade132ebe4fd2b29c8df52c5ed9cc
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author Ncde61c7380b1444eb744d65a929098f1
17 schema:citation sg:pub.10.1007/s00280-007-0588-3
18 sg:pub.10.1007/s10434-001-0347-3
19 sg:pub.10.1038/sj.bjc.6603670
20 schema:datePublished 2009-09-29
21 schema:datePublishedReg 2009-09-29
22 schema:description Background:Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.Methods:First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.Results:In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42–100) after the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and 1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P=0.002), possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701 patients treated with placebo (4.9%) underwent R0 metastasectomy (P=0.24).Conclusions:The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bevacizumab vs placebo.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N126491be7c074c2794a926091bbb14d8
26 N48c86b606f504a76844da61629824fc7
27 sg:journal.1017082
28 schema:keywords NO16966
29 NO16966 trial
30 R0 resection
31 analysis
32 beats
33 bevacizumab
34 bleeding
35 cancer
36 chemotherapy
37 colorectal cancer
38 combination chemotherapy
39 comparison
40 complete resection
41 complications
42 control
43 curative-intent surgery
44 cure
45 data
46 days
47 death
48 differences
49 different regimens
50 dose
51 efficacy
52 events
53 exploratory comparison
54 first beat
55 first-line chemotherapy
56 grade 3/4 bleeding
57 historical controls
58 last dose
59 metastasectomy
60 metastasis
61 metastatic colorectal cancer
62 overall survival
63 oxaliplatin-based chemotherapy
64 oxaliplatin-based combination chemotherapy
65 patient selection
66 patients
67 placebo
68 post-operative complications
69 rate
70 regimens
71 resection
72 resection rate
73 retrospective analysis
74 safety
75 safety of bevacizumab
76 selection
77 serious post-operative complications
78 significant differences
79 surgery
80 surgery-related deaths
81 survival
82 trials
83 wound-healing events
84 schema:name Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
85 schema:pagination 1033-1038
86 schema:productId N1fe5f609188347d39a12442ddfc8bfc6
87 N93afccedf7384d3dbf2ea933f4f5333d
88 Naf1eed4bc8bc4a3d8b6544070944836b
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048476579
90 https://doi.org/10.1038/sj.bjc.6605259
91 schema:sdDatePublished 2022-09-02T15:53
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N6d8fc0ef7cb24187827cda08e1b040c8
94 schema:url https://doi.org/10.1038/sj.bjc.6605259
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N0690699cd469474d8bfdb4cafffaeb40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Middle Aged
100 rdf:type schema:DefinedTerm
101 N0a0f6f9ef7af4b5594c36f29c85dbb97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Postoperative Complications
103 rdf:type schema:DefinedTerm
104 N0f458a6ecf704884bda34230cfc5f1c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Antibodies, Monoclonal
106 rdf:type schema:DefinedTerm
107 N126491be7c074c2794a926091bbb14d8 schema:issueNumber 7
108 rdf:type schema:PublicationIssue
109 N162d56e9d0b546dd99e21837e81c2088 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N1fe5f609188347d39a12442ddfc8bfc6 schema:name dimensions_id
113 schema:value pub.1048476579
114 rdf:type schema:PropertyValue
115 N21cdc622dd20432dbd8a98f33c69fcc9 rdf:first sg:person.015665060162.24
116 rdf:rest rdf:nil
117 N31b8d8bb1ea540ef965a270f60b53d57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Male
119 rdf:type schema:DefinedTerm
120 N32dc7b479a2d4a2588ea6804da3dc919 rdf:first sg:person.01320161130.16
121 rdf:rest N98d1c1e486844a46bfd8e05cc51ec44d
122 N363cde1cd03c4fa680dd66c7be50c1e4 schema:affiliation grid-institutes:None
123 schema:familyName Puerto
124 schema:givenName O del
125 rdf:type schema:Person
126 N48c86b606f504a76844da61629824fc7 schema:volumeNumber 101
127 rdf:type schema:PublicationVolume
128 N64f1d733f08f4482891a35969689d8a6 rdf:first sg:person.011701556564.34
129 rdf:rest N21cdc622dd20432dbd8a98f33c69fcc9
130 N66793de34d3744ce9cb1a309df6d695b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Neoplasm Metastasis
132 rdf:type schema:DefinedTerm
133 N66944744b3804856a4cf4dea84934a36 rdf:first sg:person.01214007230.69
134 rdf:rest N64f1d733f08f4482891a35969689d8a6
135 N6d8fc0ef7cb24187827cda08e1b040c8 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 N81c4d5ee2a2b4cccb5261358409a8a67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Female
139 rdf:type schema:DefinedTerm
140 N9378d53606ae4bd4b669e17354d441dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Antibodies, Monoclonal, Humanized
142 rdf:type schema:DefinedTerm
143 N93afccedf7384d3dbf2ea933f4f5333d schema:name doi
144 schema:value 10.1038/sj.bjc.6605259
145 rdf:type schema:PropertyValue
146 N93f776b132f341b880fdf64600080324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Combined Modality Therapy
148 rdf:type schema:DefinedTerm
149 N9436d8006012454a9a7e7628dd98c1a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Angiogenesis Inhibitors
151 rdf:type schema:DefinedTerm
152 N98d1c1e486844a46bfd8e05cc51ec44d rdf:first sg:person.01035560774.45
153 rdf:rest N66944744b3804856a4cf4dea84934a36
154 N9c4d01ea3eaf4b3eb8cccedad0cbf429 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Colorectal Neoplasms
156 rdf:type schema:DefinedTerm
157 Na8de514677c847ab9f49ea6bbadb9556 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Antineoplastic Combined Chemotherapy Protocols
159 rdf:type schema:DefinedTerm
160 Naf1eed4bc8bc4a3d8b6544070944836b schema:name pubmed_id
161 schema:value 19789532
162 rdf:type schema:PropertyValue
163 Nbf12d52be9ad42f29df2596b2a8e659c rdf:first N363cde1cd03c4fa680dd66c7be50c1e4
164 rdf:rest N32dc7b479a2d4a2588ea6804da3dc919
165 Ncde61c7380b1444eb744d65a929098f1 rdf:first sg:person.011120523514.08
166 rdf:rest Nbf12d52be9ad42f29df2596b2a8e659c
167 Ndffade132ebe4fd2b29c8df52c5ed9cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Bevacizumab
169 rdf:type schema:DefinedTerm
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1017082 schema:issn 0007-0920
177 1532-1827
178 schema:name British Journal of Cancer
179 schema:publisher Springer Nature
180 rdf:type schema:Periodical
181 sg:person.01035560774.45 schema:affiliation grid-institutes:grid.5072.0
182 schema:familyName Chau
183 schema:givenName I
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45
185 rdf:type schema:Person
186 sg:person.011120523514.08 schema:affiliation grid-institutes:grid.5072.0
187 schema:familyName Okines
188 schema:givenName A
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120523514.08
190 rdf:type schema:Person
191 sg:person.011701556564.34 schema:affiliation grid-institutes:grid.51462.34
192 schema:familyName Saltz
193 schema:givenName L
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011701556564.34
195 rdf:type schema:Person
196 sg:person.01214007230.69 schema:affiliation grid-institutes:grid.410569.f
197 schema:familyName Van Cutsem
198 schema:givenName E
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214007230.69
200 rdf:type schema:Person
201 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.5072.0
202 schema:familyName Cunningham
203 schema:givenName D
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
205 rdf:type schema:Person
206 sg:person.015665060162.24 schema:affiliation grid-institutes:grid.11485.39
207 schema:familyName Cassidy
208 schema:givenName J
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015665060162.24
210 rdf:type schema:Person
211 sg:pub.10.1007/s00280-007-0588-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029987674
212 https://doi.org/10.1007/s00280-007-0588-3
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/s10434-001-0347-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015538540
215 https://doi.org/10.1007/s10434-001-0347-3
216 rdf:type schema:CreativeWork
217 sg:pub.10.1038/sj.bjc.6603670 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040702997
218 https://doi.org/10.1038/sj.bjc.6603670
219 rdf:type schema:CreativeWork
220 grid-institutes:None schema:alternateName F Hoffman La Roche Ltd, Welwyn Garden City, UK
221 schema:name F Hoffman La Roche Ltd, Welwyn Garden City, UK
222 rdf:type schema:Organization
223 grid-institutes:grid.11485.39 schema:alternateName Cancer Research UK, Glasgow, UK
224 schema:name Cancer Research UK, Glasgow, UK
225 rdf:type schema:Organization
226 grid-institutes:grid.410569.f schema:alternateName Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium
227 schema:name Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium
228 rdf:type schema:Organization
229 grid-institutes:grid.5072.0 schema:alternateName Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
230 schema:name Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
231 rdf:type schema:Organization
232 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center, New York City, NY, USA
233 schema:name Memorial Sloan Kettering Cancer Center, New York City, NY, USA
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...